GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » ROC %

Unipharma Co (ROCO:6621) ROC % : -20.66% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Unipharma Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was -20.66%.

As of today (2025-04-03), Unipharma Co's WACC % is 3.00%. Unipharma Co's ROC % is -19.76% (calculated using TTM income statement data). Unipharma Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Unipharma Co ROC % Historical Data

The historical data trend for Unipharma Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co ROC % Chart

Unipharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.35 -23.28 -15.13 -19.21 -21.53

Unipharma Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.64 -13.46 -25.93 -17.31 -20.66

Unipharma Co ROC % Calculation

Unipharma Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

ROC % (A: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2023 ) + Invested Capital (A: Dec. 2024 ))/ count )
=-30.821 * ( 1 - 0% )/( (142.175 + 144.177)/ 2 )
=-30.821/143.176
=-21.53 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=350.074 - 33.718 - ( 174.181 - max(0, 37.116 - 226.228+174.181))
=142.175

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=328.976 - 25.97 - ( 158.829 - max(0, 33.152 - 200.013+158.829))
=144.177

Unipharma Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-33.636 * ( 1 - 0% )/( (181.465 + 144.177)/ 2 )
=-33.636/162.821
=-20.66 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=328.976 - 25.97 - ( 158.829 - max(0, 33.152 - 200.013+158.829))
=144.177

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Unipharma Co  (ROCO:6621) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Unipharma Co's WACC % is 3.00%. Unipharma Co's ROC % is -19.76% (calculated using TTM income statement data). Unipharma Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Unipharma Co ROC % Related Terms

Thank you for viewing the detailed overview of Unipharma Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Unipharma Co Business Description

Traded in Other Exchanges
N/A
Address
Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines